Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 24,000 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $26.00, for a total transaction of $624,000.00. Following the sale, the vice president now directly owns 24,000 shares in the company, valued at $624,000. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Heron Therapeutics stock opened at $26.61 on Wednesday. Heron Therapeutics Inc has a one year low of $15.68 and a one year high of $29.49. The business’s fifty day moving average is $21.72 and its 200 day moving average is $19.08. The stock has a market capitalization of $2.30 billion, a PE ratio of -10.91 and a beta of 1.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.76 and a quick ratio of 3.51.
Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.15. The business had revenue of $42.62 million during the quarter, compared to analyst estimates of $34.02 million. Heron Therapeutics had a negative return on equity of 60.76% and a negative net margin of 140.55%. Heron Therapeutics’s revenue was up 115.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.49) EPS. As a group, sell-side analysts expect that Heron Therapeutics Inc will post -2.44 EPS for the current fiscal year.
HRTX has been the subject of several recent analyst reports. JMP Securities decreased their target price on shares of Heron Therapeutics from $38.00 to $32.00 and set a “market outperform” rating for the company in a report on Thursday, October 3rd. Northland Securities reiterated a “buy” rating and set a $47.00 price target on shares of Heron Therapeutics in a report on Wednesday, November 13th. BidaskClub raised shares of Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 26th. Cowen reissued a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Tuesday, October 1st. Finally, Evercore ISI restated a “buy” rating and issued a $75.00 price objective on shares of Heron Therapeutics in a report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $46.13.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: Initial Coin Offering (ICO)
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.